Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Held

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
Plos One|December 3, 2015
Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial PneumoniasMarius M Hoeper, Juergen Behr, Matthias Held, et al.
ESC Heart Failure|March 4, 2025
Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysisDirk Skowasch, Christine Pausch, Doerte Huscher, et al.
Thrombosis Research|May 18, 2023
Unsupervised clustering of venous thromboembolism patients by clinical features at presentation identifies novel endotypes that improve prognostic stratificationAlejandro Pallares Robles, Vincent Ten Cate, Michael Lenz, et al.
International Journal of Cardiology|January 7, 2012
Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011H Ardeschir Ghofrani, Oliver Distler, Felix Gerhardt, et al.
NPJ Genomic Medicine|March 26, 2025
Pathogenic SMAD6 variants in patients with idiopathic and complex congenital heart disease associated pulmonary arterial hypertensionSofia Karl, Ekkehard Grünig, Memoona Shaukat, et al.
ERJ Open Research|December 10, 2025
Survival in patients with chronic thromboembolic pulmonary hypertension treated with riociguat <i>versus</i> other medications: a COMPERA analysisMatthias Held, Christine Pausch, Doerte Huscher, et al.
The European Respiratory Journal|May 9, 2020
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registryJürgen Behr, Antje Prasse, Hubert Wirtz, et al.
Respiratory Research|March 17, 2019
The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registryMichael Kreuter, Jeff Swigris, David Pittrow, et al.
Respiratory Research|July 16, 2017
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registryMichael Kreuter, Jeff Swigris, David Pittrow, et al.
Deutsche Medizinische Wochenschrift (1946)|July 6, 2019
[Hemodynamic Definition of Pulmonary Hypertension: Commentary on the Proposed Change by the 6th World Symposium on Pulmonary Hypertension]Stephan Rosenkranz, Gerhard-Paul Diller, Daniel Dumitrescu, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Plos One|December 3, 2015
Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial PneumoniasMarius M Hoeper, Juergen Behr, Matthias Held, et al.
ESC Heart Failure|March 4, 2025
Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysisDirk Skowasch, Christine Pausch, Doerte Huscher, et al.
Thrombosis Research|May 18, 2023
Unsupervised clustering of venous thromboembolism patients by clinical features at presentation identifies novel endotypes that improve prognostic stratificationAlejandro Pallares Robles, Vincent Ten Cate, Michael Lenz, et al.
International Journal of Cardiology|January 7, 2012
Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011H Ardeschir Ghofrani, Oliver Distler, Felix Gerhardt, et al.
NPJ Genomic Medicine|March 26, 2025
Pathogenic SMAD6 variants in patients with idiopathic and complex congenital heart disease associated pulmonary arterial hypertensionSofia Karl, Ekkehard Grünig, Memoona Shaukat, et al.
ERJ Open Research|December 10, 2025
Survival in patients with chronic thromboembolic pulmonary hypertension treated with riociguat <i>versus</i> other medications: a COMPERA analysisMatthias Held, Christine Pausch, Doerte Huscher, et al.
The European Respiratory Journal|May 9, 2020
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registryJürgen Behr, Antje Prasse, Hubert Wirtz, et al.
Respiratory Research|March 17, 2019
The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registryMichael Kreuter, Jeff Swigris, David Pittrow, et al.
Respiratory Research|July 16, 2017
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registryMichael Kreuter, Jeff Swigris, David Pittrow, et al.
Deutsche Medizinische Wochenschrift (1946)|July 6, 2019
[Hemodynamic Definition of Pulmonary Hypertension: Commentary on the Proposed Change by the 6th World Symposium on Pulmonary Hypertension]Stephan Rosenkranz, Gerhard-Paul Diller, Daniel Dumitrescu, et al.
Pageof 11